Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• In relapsed/refractory multiple myeloma (RRMM) patients, isatuximab combined with or IMiDs or PIs plus dexamethasone significantly improved progression-free survival (PFS) (HR (hazard ratio): 0.552) and overall survival (OS) (HR: 0.737) compared to IMiDs or PIs plus dexamethasone alone.
• Isatuximab-based treatments showed higher overall response rates (ORR) compared to bortezomib/dexamethasone and lenalidomide/dexamethasone, with triple-drug regimens demonstrating the best probabilities for achieving superior ORRs.
• In specific subgroups, isatuximab significantly improved HR: 0.552, 95% CI (confidence interval) = 0.461 to 0.659, 95% PI = 0.318 to 0.957 (PFS) in multiple myeloma patients with +1q, and in lenalidomide-refractory multiple myeloma, isatuximab/pomalidomide/dexamethasone showed superior efficacy compared to dexamethasone alone.
• Isatuximab-based treatments were noted for producing the best treatment response quality for RRMM, with similar efficacy to daratumumab-based regimens.
• In patients treated with isatuximab-based regimens combined with IMiDs or PIs plus dexamethasone, higher rates of hematologic adverse events such as thrombocytopenia and neutropenia, and nonhematologic adverse events like upper respiratory tract infections, pneumonia, bronchitis, dyspnea, diarrhea, pyrexia, and fatigue, were observed.
• Infections, including pneumonia and upper respiratory tract infections, were more frequent in patients receiving anti-CD38 mAbs, including isatuximab, although there was no significant increased risk for varicella-zoster virus reactivation.
• Neutropenia (32.1%) was the most common hematologic adverse event, while cough (43.3%) was the most frequent nonhematologic event in various isatuximab-based triplet regimens. Severe adverse events were more common in regimens including isatuximab, panobinostat, and pomalidomide.
• Isatuximab demonstrated improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM), especially in subgroups with +1q chromosome abnormality and lenalidomide-refractory disease. These subgroups showed superior efficacy when treated with isatuximab-based regimens compared to standard therapies, highlighting its relevance in these specific populations.